stoxline Quote Chart Rank Option Currency Glossary
  
I-Mab (IMAB)
0.9638  0.014 (1.45%)    02-14 16:00
Open: 0.98
High: 0.99
Volume: 328,314
  
Pre. Close: 0.95
Low: 0.942
Market Cap: 74(M)
Technical analysis
2025-02-14 4:48:57 PM
Short term     
Mid term     
Targets 6-month :  1.23 1-year :  1.33
Resists First :  1.05 Second :  1.13
Pivot price 0.98
Supports First :  0.93 Second :  0.77
MAs MA(5) :  0.95 MA(20) :  1
MA(100) :  1.08 MA(250) :  1.38
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  15 D(3) :  14.1
RSI RSI(14): 45.3
52-week High :  2 Low :  0.84
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ IMAB ] has closed above bottom band by 37.4%. Bollinger Bands are 48.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.99 - 1 1 - 1
Low: 0.93 - 0.93 0.93 - 0.94
Close: 0.95 - 0.96 0.96 - 0.97
Company Description

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Headline News

Tue, 04 Feb 2025
I-Mab to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference - GlobeNewswire

Tue, 04 Feb 2025
Key Oncology Developments: I-Mab's Strategic Presentation at Major Healthcare Conference - StockTitan

Mon, 03 Feb 2025
Significant layoffs amid I-Mab restructuring - The Pharma Letter

Mon, 13 Jan 2025
I-Mab Biopharma Advances Precision Immuno-Oncology Programs Post-China Divestiture - TipRanks

Wed, 08 Jan 2025
I-Mab Chairman plans $2 million ADS purchase - Investing.com

Wed, 08 Jan 2025
I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 82 (M)
Held by Insiders 1.1042e+008 (%)
Held by Institutions 11.1 (%)
Shares Short 533 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.6925e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -4 %
Return on Assets (ttm) 938.2 %
Return on Equity (ttm) -29.3 %
Qtrly Rev. Growth 3.49e+006 %
Gross Profit (p.s.) 0
Sales Per Share -66.41
EBITDA (p.s.) 3.23148e+006
Qtrly Earnings Growth -2.5 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow 0.04
Stock Dividends
Dividend 0
Forward Dividend 591160
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android